Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy

被引：0
|
作者：
de Gramont Lesparre, A. H. [1 ,2 ,3 ,4 ]
Chibaudel, B. [1 ,2 ,3 ,4 ]
Bourges, O. [1 ,2 ,3 ,4 ]
Perez-Staub, N. [1 ,2 ,3 ,4 ]
Tournigand, C. [1 ,2 ,3 ,4 ]
Maindrault-Goebel, F. [1 ,2 ,3 ,4 ]
Andre, T. [1 ,2 ,3 ,4 ]
Larsen, A. K. [1 ,2 ,3 ,4 ]
Afchain, P. [1 ,2 ,3 ,4 ]
Louvet, C. [1 ,2 ,3 ,4 ]
机构：
[1] Hop St Antoine, F-75571 Paris, France
[2] GERCOR, Multidisciplinary Grp Canc Res, Paris, France
[3] Hop La Pitie Salpetriere, Paris, France
[4] INSERM, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4024
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer
    Ramanathan, RK
    Clark, JW
    Kemeny, NE
    Lenz, HJ
    Gococo, KO
    Haller, DG
    Mitchell, EP
    Kardinal, CG
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) : 2904 - 2911
  • [32] Impact of Fluoropyrimidine and Oxaliplatin-based Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
    Okada, Yuka
    Ozawa, Tsuyoshi
    Hayama, Tamuro
    Ohno, Kohei
    Tsukamoto, Mitsuo
    Fukushima, Yoshihisa
    Shimada, Ryu
    Nozawa, Keijiro
    Matsuda, Keiji
    Hashiguchi, Yojiro
    IN VIVO, 2021, 35 (01): : 593 - 601
  • [33] Oxaliplatin-based neoadjuvant chemoradiation for locally advanced rectal cancer
    Kazmi, S. S.
    Azfar, M.
    Syed, A. A.
    Yusuf, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy
    L Paré-Brunet
    A Sebio
    J Salazar
    A Berenguer-Llergo
    E Río
    A Barnadas
    M Baiget
    D Páez
    The Pharmacogenomics Journal, 2015, 15 : 397 - 404
  • [35] Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy
    Pare-Brunet, L.
    Sebio, A.
    Salazar, J.
    Berenguer-Llergo, A.
    Rio, E.
    Barnadas, A.
    Baiget, M.
    Paez, D.
    PHARMACOGENOMICS JOURNAL, 2015, 15 (05): : 397 - 404
  • [36] Prevalence and risk factors of chronic neuropathy in 225 colorectal cancer patients treated with oxaliplatin-based regimens in Tunisia
    Zribi, A.
    Ben Nasr, S.
    Ahmed, M.
    Mansouri, N.
    Balti, M.
    Fendri, S.
    Haddauoi, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S99 - S100
  • [37] PKM2 as a biomarker for sensitivity to oxaliplatin-based chemotherapy in metastatic colorectal cancer (mCRC).
    Papadaki, C.
    Saridaki, Z.
    Tzardi, M.
    Sfakianaki, M.
    Sfakiotaki, G.
    Trypaki, M.
    Messaritakis, I.
    Mavroudis, D.
    Georgoulias, V.
    Sougklakos, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [38] Neutropenia in colorectal cancer treated with oxaliplatin-based hyperthermic intraperitoneal chemotherapy: An observational cohort study
    Peter H Cashin
    Lana Ghanipour
    Malin Enblad
    David L Morris
    World Journal of Gastrointestinal Oncology, 2020, (05) : 549 - 558
  • [39] Neutropenia in colorectal cancer treated with oxaliplatin-based hyperthermic intraperitoneal chemotherapy: An observational cohort study
    Cashin, Peter H.
    Ghanipour, Lana
    Enblad, Malin
    Morris, David L.
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 12 (05) : 549 - 558
  • [40] Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer
    Kuo, T
    Cho, CD
    Halsey, J
    Wakelee, HA
    Advani, RH
    Ford, JM
    Fisher, GA
    Sikic, BI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5613 - 5619
12345